FA plus ropivacaine

PreclinicalSmall molecule

BBeijing Tiantan Hospital

FA plus ropivacaine is one of 3 small molecule programs targeting Infiltration. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

InfiltrationSuspended

InfiltrationPreclinical

Suspended

Competition

Competitive Landscape

5 competitors in Infiltration

#DrugCompanyPhaseTrials

Intrathecal Fentanyl

MMansoura University

Preclinical

1 2

Buffered Lidocaine

UUniversity of California, San Diego

Preclinical

1 3

FA plus ropivacaine

BBeijing Tiantan Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Infiltration1 trial

Flurbiprofen Axetil as an Adjuvant to Pre-emptive Scalp Infiltration

Suspended·—·N/A·NCT05624359·216 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for FA plus ropivacaine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — FA plus ropivacaine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for FA plus ropivacaine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Beijing Tiantan Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: BBeijing Tiantan Hospital

FA plus ropivacaine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Infiltration1 trial

References

Drug Info

Quick Facts

Related News